Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
Q-REstrain is a breakthrough in personalized, autologous therapy for cancer—a sophisticated non-manipulated, personalized therapy that targets the specific genetic sequences driving a patient’s cancer, viral infections, or Lyme disease and inhibits expression of those genetic sequences. This innovative personalized, autologous therapy goes beyond traditional approaches by creating a uniquely tailored treatment designed specifically for individual needs.
Autologous Therapy
Q-REstrain is completely personalized to the patient. Using a simple blood sample, our laboratory scientists analyze the patient’s specific genetic markers to create a therapy that targets only the desired genes.
Gene Silencing
Q-REstrain utilizes advanced RNA technology to "silence" problematic genetic sequences. This advanced therapy in cancer uses small oligonucleotide molecules that are complementary to specific gene sequences, effectively turning off the signals that allow certain cancers, viruses, or Lyme disease to thrive through precise gene silencing technology. By blocking specific messenger RNA (mRNA) sequences, Q-REstrain prevents proteins essential for cell survival or metabolism from being produced in your body.
Q-REstrain takes advantage of oligonucleotide molecules – microRNAs isolated by the patient’s sample. The Q-REstrain molecule has a potent ability to block specific mRNA with a very high rate of specificity; therefore expression of only the desired gene is inhibited.
Certified RGCC practitioners receive training and support through RGCC college and the RGCC practitioner network.
Patient connects with a trained RGCC practitioner who evaluates their case and determines if Q-REstrain is a good fit.
Patient completes required diagnostic tests (Oncotrace for cancer or serum lab work for virus/Lyme).
Patient provides blood sample for personalized therapy development.
Customized Q-REstrain therapy is created in our state-of-the-art laboratory (14 working days).
Patient receives personalized therapy through an RGCC practitioner.
Q-REstrain therapy offers hope and healing for patients facing multiple challenging conditions:
Solid Tumors: Effective for most solid tumor types across various stages Hematologic Malignancies: Blood cancers including leukemias, lymphomas, and myelomas
Note: CNS (central nervous system) cancers are not suitable for Q-REstrain therapy
Q-REstrain successfully targets a comprehensive range of viral infections, such as:
Herpes Viruses: HSV1/HSV2, HHV6, Varicella Zoster (shingles), Epstein-Barr Virus (EBV), Cytomegalovirus (CMV)
Human Papilloma Virus: HPV-16/18 and HPV-6/11
Hepatitis: Hepatitis B and C viruses
Other Viruses: Coxsackie Virus, HIV, HTLV1
Targeted treatment for Lyme disease and associated co-infections, helping patients overcome these complex, chronic conditions.
Explore scientific papers and articles regarding antisense oligonucleotide therapy.
Q-REstrain therapy has been extensively studied with thousands of research studies confirming its safety profile. The therapy is well-tolerated by most patients, with a strong track record of successful outcomes across diverse patient populations.
Sample of Studies:
Safety of antisense oligonucleotide and siRNA-based therapeutics
Antisense oligonucleotides as therapeutic agents
In vivo and in vitro studies of antisense oligonucleotides – a review
Therapeutic Antisense Oligonucleotides Are Coming of Age
Antisense oligonucleotides: absorption, distribution, metabolism, and excretion
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
The powerful world of antisense oligonucleotides: From bench to bedside
RNA-Based Therapeutics: From Antisense Oligonucleotides to miRNAs
For Cancer Patients:
For Viral or Lyme Patients:
Cancer: Maximum of 4 treatments per 12-month period, spaced a minimum of 3 months apart
Viral/Lyme: Maximum of 9 treatments per 12-month period, spaced a minimum of 21 days apart
Important:
Mandatory Follow-Up Tests
While generally well-tolerated, some patients may experience:
Absolute Contraindications:
Age Restrictions:
Special Considerations
Patients with large tumor burden require careful evaluation for Tumor Lysis Syndrome risk before treatment.
Patients should consult with their RGCC Practitioner about other potential contraindications.
Q-REstrain therapy demonstrates remarkable success rates across different conditions:
Clinical outcomes are defined as complete response, partial response, or disease stabilization. Individual results may vary, and success encompasses any positive response, from complete eradication to disease stabilization.
Precision Personalization: Every Q-REstrain therapy is uniquely designed for your specific genetic profile—no one-size-fits-all approach to personalized therapy and cancer.
Long-Lasting Action: A single treatment works continuously for up to six months, providing sustained therapeutic benefit through advanced gene silencing.
Minimally Invasive: Requires only a simple blood draw for analysis and a single IV treatment for this targeted personalized therapy.
Cutting-Edge Science: Utilizes the latest RNA interference technology backed by thousands of safety studies in cancer personalized therapy.
Comprehensive Coverage: Effective against cancers, multiple viral infections, and Lyme disease.
Proven Results: High success rates with excellent safety profile across diverse patient populations.
Expert Support: Treatment guided by RGCC-trained practitioners with specialized expertise in personalized medicine.
Take control of your health journey with personalized gene silencing therapy.
Q-REstrain offers hope through precision personalized therapy for cancer—targeting the specific genetic drivers of your condition while preserving your healthy cells. Our expert team is ready to guide you through this innovative autologous, personalized therapy treatment option.
Contact RGCC today to discuss whether Q-REstrain therapy is right for you.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
